Clarity Pharmaceuticals Ltd (CU6.AX)
Clarity Pharmaceuticals Ltd operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $2.76, down 1.78% on the session, giving a market capitalisation of $1.03B. Its beta of 1.18 implies it has historically moved more than the broad market.
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Clarity Pharmaceuticals Ltd is most often compared with the following Healthcare names: